Vertex Pharmaceuticals Inc
VRTX501.030USD
-8.470-1.66%
交易中 （美东）报价延迟15分钟
128.73B总市值
亏损市盈率 TTM
关于 Vertex Pharmaceuticals Inc 公司
Vertex Pharmaceuticals Incorporated 是一家全球性生物技术公司。该公司专注于投资科学创新，为患有严重疾病的人创造变革性药物，重点关注专业市场。该公司拥有四种获批的治疗囊性纤维化 (CF) 潜在病因的药物，以及一种获批的治疗严重镰状细胞病 (SCD) 和输血依赖性β地中海贫血 (TDT) 的疗法。其产品线包括 CF、SCD、TDT、急性和神经性疼痛、APOL1 介导的肾脏疾病、1 型糖尿病、1 型肌强直性营养不良和 α-1 抗胰蛋白酶缺乏症的临床阶段项目。其上市药物包括 TRIKAFTA/KAFTRIO、SYMDEKO/SYMKEVI（tezacaftor/ivacaftor 和 ivacaftor）、ORKAMBI（lumacaftor/ivacaftor）和 KALYDECO（ivacaftor）。该公司正在开发非自体（同种异体）完全分化、干细胞衍生的胰岛细胞疗法，旨在取代 1 型糖尿病患者体内被破坏的产生胰岛素的胰岛细胞。
公司简介
公司代码VRTX
公司名称Vertex Pharmaceuticals Inc
上市日期Jul 24, 1991
成立日期1989
CEODr. Reshma Kewalramani
员工数量6100
证券类型Ordinary Share
年结日Jul 24
公司地址50 Northern Avenue
城市BOSTON
上市交易所NASDAQ Global Select Consolidated
国家United States of America
邮编02210
电话16173416393
网址https://www.vrtx.com/
公司代码VRTX
上市日期Jul 24, 1991
成立日期1989
公司高管
名称
名称/职务
职务
持股
持股变动
Dr. Reshma Kewalramani
Dr. Reshma Kewalramani
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
41.81K
+38.72%
Mr. Bruce I. Sachs
Mr. Bruce I. Sachs
Lead Independent Director
Lead Independent Director
40.00K
--
Dr. Carmen Bozic, M.D.
Dr. Carmen Bozic, M.D.
Executive Vice President - Global Medicines Development and Medical Affairs, Chief Medical Officer
Executive Vice President - Global Medicines Development and Medical Affairs, Chief Medical Officer
32.67K
+40.46%
Dr. Ourania (Nia) Tatsis, Ph.D.
Dr. Ourania (Nia) Tatsis, Ph.D.
Executive Vice President, Chief Regulatory and Quality Officer
Executive Vice President, Chief Regulatory and Quality Officer
30.30K
+19.95%
Dr. Jeffrey M. (Jeff) Leiden, M.D., Ph.D.
Dr. Jeffrey M. (Jeff) Leiden, M.D., Ph.D.
Executive Chairman of the Board
Executive Chairman of the Board
24.47K
--
Mr. Stuart A. Arbuckle
Mr. Stuart A. Arbuckle
Chief Operating Officer, Executive Vice President
Chief Operating Officer, Executive Vice President
23.68K
+38.42%
Mr. Jonathan Biller, J.D.
Mr. Jonathan Biller, J.D.
Executive Vice President, Chief Legal Officer
Executive Vice President, Chief Legal Officer
17.61K
+5.74%
Ms. Diana L. Mckenzie
Ms. Diana L. Mckenzie
Independent Director
Independent Director
8.63K
+485.29%
Mr. Lloyd A. Carney
Mr. Lloyd A. Carney
Independent Director
Independent Director
6.32K
--
Dr. Sangeeta N. Bhatia, M.D., Ph.D.
Dr. Sangeeta N. Bhatia, M.D., Ph.D.
Independent Director
Independent Director
4.43K
--
查看更多
名称
名称/职务
职务
持股
持股变动
Dr. Reshma Kewalramani
Dr. Reshma Kewalramani
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
41.81K
+38.72%
Mr. Bruce I. Sachs
Mr. Bruce I. Sachs
Lead Independent Director
Lead Independent Director
40.00K
--
Dr. Carmen Bozic, M.D.
Dr. Carmen Bozic, M.D.
Executive Vice President - Global Medicines Development and Medical Affairs, Chief Medical Officer
Executive Vice President - Global Medicines Development and Medical Affairs, Chief Medical Officer
32.67K
+40.46%
Dr. Ourania (Nia) Tatsis, Ph.D.
Dr. Ourania (Nia) Tatsis, Ph.D.
Executive Vice President, Chief Regulatory and Quality Officer
Executive Vice President, Chief Regulatory and Quality Officer
30.30K
+19.95%
Dr. Jeffrey M. (Jeff) Leiden, M.D., Ph.D.
Dr. Jeffrey M. (Jeff) Leiden, M.D., Ph.D.
Executive Chairman of the Board
Executive Chairman of the Board
24.47K
--
Mr. Stuart A. Arbuckle
Mr. Stuart A. Arbuckle
Chief Operating Officer, Executive Vice President
Chief Operating Officer, Executive Vice President
23.68K
+38.42%
收入明细
单位: USD更新时间: 4月6日 周日
单位: USD更新时间: 4月6日 周日
FY2024
FY2024Q4
FY2024Q3
FY2024Q2
FY2024Q1
FY2023
FY2023Q4
FY2023Q3
FY2023Q2
FY2023Q1
FY2022
FY2022Q4
FY2022Q3
FY2022Q2
FY2022Q1
FY2021
FY2020
FY2019
FY2018
业务USD
名称
营收
占比
TRIKAFTA
10.24B
92.91%
Other CF products
781.50M
7.09%
地区USD
名称
营收
占比
United States
6.68B
60.66%
Europe
3.45B
31.34%
Other
881.30M
8.00%
业务
地区
业务USD
名称
营收
占比
TRIKAFTA
10.24B
92.91%
Other CF products
781.50M
7.09%
股东统计
更新时间: 2月21日 周五
更新时间: 2月21日 周五
持股股东
股东类型
持股股东
股东统计
占比
Capital World Investors
11.02%
The Vanguard Group, Inc.
9.00%
BlackRock Institutional Trust Company, N.A.
5.57%
State Street Global Advisors (US)
4.66%
Capital Research Global Investors
4.06%
Other
65.69%
持股股东
股东统计
占比
Capital World Investors
11.02%
The Vanguard Group, Inc.
9.00%
BlackRock Institutional Trust Company, N.A.
5.57%
State Street Global Advisors (US)
4.66%
Capital Research Global Investors
4.06%
Other
65.69%
股东类型
股东统计
占比
Investment Advisor
48.67%
Investment Advisor/Hedge Fund
37.50%
Pension Fund
2.67%
Research Firm
2.17%
Bank and Trust
1.87%
Sovereign Wealth Fund
1.44%
Hedge Fund
1.43%
Individual Investor
0.13%
Insurance Company
0.10%
Other
4.04%
机构持股
更新时间: 1月19日 周日
更新时间: 1月19日 周日
报告期
机构数
持股数
持股占比
持股变动
2025Q1
2878
247.84M
96.41%
-3.72M
2024Q4
2877
248.76M
96.87%
-2.25M
2024Q3
2786
247.87M
96.18%
-4.19M
2024Q2
2747
248.36M
96.27%
-4.14M
2024Q1
2680
247.63M
95.87%
-4.48M
2023Q4
2608
247.92M
96.20%
-4.51M
2023Q3
2477
248.64M
96.45%
-6.19M
2023Q2
2488
248.89M
96.55%
-7.11M
2023Q1
2468
250.11M
97.13%
-4.74M
2022Q4
2454
248.59M
96.73%
-7.80M
查看更多
股东持股明细
名称
持股数
占比
持股变动
变动比例
公告日期
Capital World Investors
28.33M
11.02%
+1.51M
+5.65%
Dec 31, 2024
The Vanguard Group, Inc.
23.15M
9%
+102.48K
+0.44%
Dec 31, 2024
BlackRock Institutional Trust Company, N.A.
14.33M
5.57%
-90.57K
-0.63%
Dec 31, 2024
State Street Global Advisors (US)
11.98M
4.66%
+163.16K
+1.38%
Dec 31, 2024
Capital Research Global Investors
10.43M
4.06%
+1.43M
+15.85%
Dec 31, 2024
Fidelity Management & Research Company LLC
9.11M
3.54%
-1.25M
-12.07%
Dec 31, 2024
Wellington Management Company, LLP
5.92M
2.3%
+1.12M
+23.28%
Dec 31, 2024
Geode Capital Management, L.L.C.
5.65M
2.2%
-287.65K
-4.85%
Dec 31, 2024
Invesco Capital Management (QQQ Trust)
5.33M
2.07%
+71.48K
+1.36%
Feb 28, 2025
JP Morgan Asset Management
4.62M
1.8%
-403.93K
-8.04%
Dec 31, 2024
查看更多
持股ETF
更新时间: 4月6日 周日
更新时间: 4月6日 周日
机构名称
占比
VanEck Biotech ETF
10.56%
Tema Neuroscience and Mental Health ETF
9.89%
Invesco Nasdaq Biotechnology ETF
8.48%
ProShares Ultra Nasdaq Biotechnology
8.08%
iShares Biotechnology ETF
7.22%
Indexperts Gorilla Aggressive Growth ETF
6.23%
Natixis Loomis Sayles Focused Growth ETF
4.96%
Franklin Genomic Advancements ETF
4.66%
Amplify AI Powered Equity ETF
4.21%
First Trust NYSE Arca Biotechnology Index Fund
3.65%
查看更多
VanEck Biotech ETF
占比10.56%
Tema Neuroscience and Mental Health ETF
占比9.89%
Invesco Nasdaq Biotechnology ETF
占比8.48%
ProShares Ultra Nasdaq Biotechnology
占比8.08%
iShares Biotechnology ETF
占比7.22%
Indexperts Gorilla Aggressive Growth ETF
占比6.23%
Natixis Loomis Sayles Focused Growth ETF
占比4.96%
Franklin Genomic Advancements ETF
占比4.66%
Amplify AI Powered Equity ETF
占比4.21%
First Trust NYSE Arca Biotechnology Index Fund
占比3.65%
分红派息
近5年累计派现
0.00
美元
公告日期
分红计划
股权登记日
现金发放日
除权除息日
暂无数据
拆合股
公告日期
类型
比率
暂无数据
公告日期
类型
比率
暂无数据